Dexketoprofen
Dexketoprofen has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 26, 2021: “Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models”.
See all 2 papers on dexketoprofen
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country; 4 trials, none about aging, 1 with no results posted.
None of its findings points the other way.
- 1 lab in 1 country
- 4 trials, none about aging, 1 with no results posted
- Funders: Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya and 7 more
- Animals1
What did studies of dexketoprofen find?
2Studies of dexketoprofen measured 2 outcomes: amyloid-beta plaques and cognitive impairment.
Amyloid-beta plaques
downin mice1
1 study
Amyloid-beta plaques
downin mice1
Dexketoprofen decreases amyloid-beta plaques in AD mice.
“reducing Aβ plaques in the hippocampus”
Animalsin AD micehippocampus
Genome medicine
Cognitive impairment
downin mice1
1 study
Cognitive impairment
downin mice1
Dexketoprofen decreases cognitive impairment in AD mice.
“two NSAIDs (dexketoprofen and etodolac) and two anti-hypertensives (penbutolol and bendroflumethiazide) that overturn the cognitive impairment in AD mice”
Animalsin AD micehippocampus
Genome medicine
Who is developing dexketoprofen?
1 company: Laboratorios Silanes S.A. de C.V..
- Companies
- Laboratorios Silanes S.A. de C.V.Phase 3primary dysmenorrhea, acute low back pain
Trial sponsors
Company2 trialsPhase 41,399 people
Company2 trialsPhase 3304 people